Giant cell tumor

Summary

Giant cell tumor (MONDO:0002171) is a cancer and 5 clinical trials. Top therapeutic interventions include denosumab. A subtype of neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	giant cell tumor
Mondo ID	MONDO:0002171
MeSH	D005870
DOID	DOID:200
NCIT	C3055
SNOMED CT	443790001
UMLS	C0017525
MedGen	6598
Is cancer (heuristic)	yes

Also known as: giant cell neoplasm · giant cell tumor · giant cell tumor (morphologic abnormality) · giant cell tumor (qualifier value) · giant cell tumor NOS (morphologic abnormality) · giant cell tumors (morphologic abnormality) · giant cell tumour (morphologic abnormality) · giant cell tumour (qualifier value) · giant cell tumour NOS (morphologic abnormality) · giant cell tumours · giant cell tumours (morphologic abnormality) · tumor of the giant cell · tumour of the giant cell

Disease family

This is a subtype of neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › giant cell tumor

Related subtypes (47): pre-malignant neoplasm, endocrine gland neoplasm, hematopoietic and lymphoid system neoplasm, skin neoplasm, mesenchymal cell neoplasm, epidural spinal canal neoplasm, skeletal muscle neoplasm, trophoblastic neoplasm, cancer, germ cell tumor, benign neoplasm, upper aerodigestive tract neoplasm, histiocytoma, embryonal neoplasm, head and neck neoplasm, epithelial neoplasm, reproductive system neoplasm, non-seminomatous lesion, odontogenic cyst, phosphaturic mesenchymal tumor, thyroglossal duct cyst, hamartoma, mesenchymoma, mesothelial neoplasm, peritoneal neoplasm, virus associated tumor, nail tumor, respiratory tract neoplasm, spindle cell neoplasm, mixed neoplasm, urinary system neoplasm, cystic neoplasm, childhood neoplasm, melanocytic neoplasm, digestive system neoplasm, nervous system neoplasm, neoplasm of thorax, connective tissue neoplasm, bronchial adenomas/carcinoids childhood, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, erythroplakia, retroperitoneal neoplasm, cardiovascular neoplasm, dermoid or epidermoid cyst of the central nervous system, connective and soft tissue neoplasm, NTRK fusion positive cancer, RET fusion positive cancer

Subtypes (2): malignant giant cell tumor, tenosynovial giant cell tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Denosumab	Approved (phase 4)
Narlumosbart	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Calcium.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00680992	PHASE2	COMPLETED	Study of Denosumab in Subjects With Giant Cell Tumor of Bone
NCT05463796	Not specified	RECRUITING	InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT02948088	Not specified	COMPLETED	Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
NCT05542524	Not specified	COMPLETED	Oral Care of Patients Treated With Anti-RANK-ligand Antibodies for a Giant Cell Tumour
NCT06331104	Not specified	COMPLETED	Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DENOSUMAB	4	1